Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahul Dhanda

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
The Journal of Allergy and Clinical Immunology|November 9, 2005
Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolideCeline Bergeron, Hans Peter Hauber, Mark Gotfried, et al.
The Journal of Supportive Oncology|May 4, 2006
Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)David Cella, Susan Yount, Hongyan Du, et al.
Journal of Patient-Reported Outcomes|March 12, 2025
Establishing content validity of the Dimensional Anhedonia Rating ScaleStephanie Bean, Rahul Dhanda, Christina A Graham, et al.
Journal of Patient-Reported Outcomes|January 4, 2024
The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validationRobert H Farber, Donald E Stull, Brooke Witherspoon, et al.
Patient Preference and Adherence|July 17, 2019
Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical studyRahul Dhanda, Della Varghese, Vijay R Nadipelli, et al.
Research and Reports in Urology|March 24, 2026
Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder CancerCharles C Peyton, Rahul Dhanda, Tom Burke, et al.
The Mental Health Clinician|December 22, 2023
Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart reviewJonathan M Meyer, Craig Chepke, Rimal B Bera, et al.
Urology Practice|November 11, 2025
Patient-Reported Outcomes Following UGN-102 Treatment in Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: An Analysis of 3 Clinical TrialsCharles C Peyton, Max Kates, Anagha Nadkarni, et al.
Clinical Breast Cancer|April 7, 2018
Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian CancerNeelima Denduluri, Gary H Lyman, Yunfei Wang, et al.
The Oncologist|May 8, 2013
Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reportingScott D Ramsey, Sean D Sullivan, Shelby D Reed, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The Journal of Allergy and Clinical Immunology|November 9, 2005
Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolideCeline Bergeron, Hans Peter Hauber, Mark Gotfried, et al.
The Journal of Supportive Oncology|May 4, 2006
Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)David Cella, Susan Yount, Hongyan Du, et al.
Journal of Patient-Reported Outcomes|March 12, 2025
Establishing content validity of the Dimensional Anhedonia Rating ScaleStephanie Bean, Rahul Dhanda, Christina A Graham, et al.
Journal of Patient-Reported Outcomes|January 4, 2024
The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validationRobert H Farber, Donald E Stull, Brooke Witherspoon, et al.
Patient Preference and Adherence|July 17, 2019
Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical studyRahul Dhanda, Della Varghese, Vijay R Nadipelli, et al.
Research and Reports in Urology|March 24, 2026
Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder CancerCharles C Peyton, Rahul Dhanda, Tom Burke, et al.
The Mental Health Clinician|December 22, 2023
Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart reviewJonathan M Meyer, Craig Chepke, Rimal B Bera, et al.
Urology Practice|November 11, 2025
Patient-Reported Outcomes Following UGN-102 Treatment in Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: An Analysis of 3 Clinical TrialsCharles C Peyton, Max Kates, Anagha Nadkarni, et al.
Clinical Breast Cancer|April 7, 2018
Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian CancerNeelima Denduluri, Gary H Lyman, Yunfei Wang, et al.
The Oncologist|May 8, 2013
Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reportingScott D Ramsey, Sean D Sullivan, Shelby D Reed, et al.
Pageof 3